background

Injectable Facility Development

Injectable Facility Development

Cipro Pharmaceuticals is actively constructing a state of the art injectable manufacturing facility within its existing premises.

  • The project is scheduled for completion within the next six months, after which the facility will become fully operational.
  • The design and infrastructure are aligned with global GMP standards, ensuring compliance with international regulatory expectations.
  • The facility will initially focus on the production of general injectable medicines, enabling immediate commencement of operations upon completion.
  • Integration with the existing solid oral manufacturing unit ensures synergy in operations, utilities, and quality systems, strengthening overall compliance and efficiency.
  • This expansion reflects Cipro’s strategic vision to diversify its portfolio and establish a strong presence in the injectable therapeutics segment, catering to both domestic and international markets.